Amylyx Pharmaceuticals, Inc. AMLX Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amylyx Pharmaceuticals, Inc.'s other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amylyx Pharmaceuticals, Inc.'s other commercial liabilities?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported other commercial liabilities of $11.28M in Q1 2026.
- How has Amylyx Pharmaceuticals, Inc.'s other commercial liabilities changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s other commercial liabilities decreased by 6.5% year-over-year, from $12.07M to $11.28M.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s other commercial liabilities?
- Over 3 years (2022 to 2025), Amylyx Pharmaceuticals, Inc.'s other commercial liabilities has grown at a -22.4% compound annual growth rate (CAGR), from $38.31M to $17.91M.